renal disease

Shown here are members of the team working to evaluate new drug candidates for the treatment of kidney diseases.

Kidney diseases research collaboration renewed

Vanderbilt University Medical Center and Bayer have agreed to continue a strategic research alliance to evaluate new drug candidates for the treatment of kidney diseases.

Analysis seeks to better manage infection in dialysis patients

Analysis seeks to better manage infection in dialysis patients

Implant one day may replace dialysis

Vanderbilt researchers used pharmacological manipulations to increase salt and water transport by kidney cells grown in culture, a step necessary for realizing an implantable artificial kidney device.

International Society of Nephrology honors Fogo

Agnes Fogo, MD, an internationally known expert in kidney disease at Vanderbilt University Medical Center, has won the 2019 Roscoe Robinson Award from the International Society of Nephrology (ISN).

Surprising finding in the kidney

TGF-beta signaling in the kidney was thought to be a target for reducing renal fibrosis, but Vanderbilt researchers report that fibrosis still occurs in the absence of TGF-beta signaling.

Study tracks new end-stage renal disease therapy

Researchers in Vanderbilt’s Division of Nephrology conducted a Phase 3 clinical trial to test the safety and efficacy of a new drug to treat patients with end-stage renal disease.